CurrentHealth NetPolicy CP PHAR.159

Clinical Policy: Sebelipase Alfa (Kanuma)

Policy governing medical necessity criteria, dosing, and authorization requirements for sebelipase alfa (Kanuma) for treatment of lysosomal acid lipase (LAL) deficiency for Health Net lines of business.

Policy Summary

PayerHealth Net

PolicySebelipase alfa (Kanuma) coverage

Policy CodePolicy CP PHAR.159

Change TypeNo material changes

Effective Date02.01.16

Next Review Date

Key ActionSubmit prior authorization with confirmation of LAL deficiency (enzyme assay or LIPA mutation), current weight, dosing rationale, and supporting clinical documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

J2840HCPCS code

3 mg/kgStd maintenance max

5 mg/kgMax weekly (rapid)

Commercial,HIM,MedicaidLines of business

6-12 moApproval duration

Coverage Criteria for Sebelipase alfa (Kanuma)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy — Covered when ALL of the following are met

Covered when ALL of the following are met

Initial Approval: 1) Diagnosis of lysosomal acid lipase (LAL) deficiency confirmed by either: a) enzyme assay demonstrating decreased LAL activity, OR b) pathogenic LIPA gene mutation; 2) Age > 1 month; 3) Documentation of the member's current weight (kg); 4) Requested dose does not exceed the stated maximums for the clinical presentation: standard regimen limits of 3 mg/kg every other week, OR for rapidly progressive disease presenting within the first 6 months of life follow weekly dosing limits (initial 1 mg/kg weekly with allowable escalation to 3 mg/kg weekly and up to 5 mg/kg weekly only upon documentation of suboptimal clinical response to 3 mg/kg weekly); 5) Provider submits supporting clinical documentation (office chart notes, laboratory results or other clinical information) demonstrating the diagnosis and rationale for therapy.

Approval durations vary by line of business (see policy).

Continuation Therapy — Covered when ALL of the following are met

Covered when ALL of the following are met

Continued Therapy: 1) Member is currently receiving Kanuma through the benefit or previously met initial approval criteria; 2) Evidence of clinical benefit on therapy as documented in the medical record — examples include: for infants with rapidly progressive disease: continued survival; for other patients: improvement in lipid parameters (decrease in LDL‑c, non‑HDL‑c or triglycerides; increase in HDL‑c), normalization of ALT/AST, reduction in hepatic fat content/steatosis or liver volume; 3) Documentation of current weight (kg) for dosing; 4) If a dose increase is requested, the new dose must not exceed the policy maximums (3 mg/kg every other week standard; for rapidly progressive disease presenting within first 6 months of life up to 5 mg/kg weekly only upon documented suboptimal response to 3 mg/kg weekly).

Approval durations: Medicaid/HIM 12 months; Commercial 6 months or to member renewal date.

Coverage is not authorized for uses that are non–FDA approved indications and not addressed by this policy unless the request includes sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy for the member’s line of business. Refer to the off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), and CP.PMN.53 (Medicaid) for the required supporting evidence and documentation standards.

Requests for therapy for indications not listed in this policy that do not meet the off‑label documentation requirements or have not followed the applicable non‑formulary processes are considered not authorized. For formulary and PDL exceptions, follow the relevant no‑coverage or non‑formulary policies for the member’s line of business (e.g., CP.CPA.190, HIM.PA.33, CP PMN.255 for no coverage; HIM.PA.103, CP PMN.16 for non‑formulary processes) or submit evidence per the off‑label use policies referenced above.

Initial Therapy Dosing and Requirements

Initial Therapy Dosing — initial dosing and approval requirements

Initial dosing and approval requirements

Initial dosing and criteria: 1) Diagnosis confirmed by enzyme assay demonstrating LAL activity deficiency or by LIPA gene mutation; 2) Age > 1 month; 3) Documentation of current weight (kg); 4) Dosing per clinical presentation: a) Standard presentation: initiate 1 mg/kg IV every other week with allowance to escalate to 3 mg/kg every other week for suboptimal response (maximum 3 mg/kg every other week); b) Rapidly progressive disease presenting within first 6 months of life: initiate 1 mg/kg IV once weekly, increase to 3 mg/kg once weekly for suboptimal response, and further increase to 5 mg/kg once weekly only if continued suboptimal clinical response to 3 mg/kg once weekly (maximum 5 mg/kg weekly); 5) Provider must submit clinical documentation supporting indication and dosing rationale.

Dose escalation to higher levels requires documentation of suboptimal clinical response (see definitions).

Continuation Therapy Requirements

Continuation Therapy — requires current therapy and documented clinical response

Continuation criteria require current therapy and documented clinical response.

Continuation: 1) Member is currently receiving therapy via the benefit or previously met initial approval; 2) Documented positive clinical response while on therapy — examples: survival for infants with rapidly progressive disease; improvements in lipid parameters (decrease in LDL‑c, non‑HDL‑c, or triglycerides; increase in HDL‑c); normalization of ALT/AST; reduction in hepatic fat content, steatosis, or liver volume; 3) Documentation of current weight (kg) for dosing; 4) Any requested dose increase must comply with policy maximums (3 mg/kg every other week standard; for rapidly progressive disease presenting within first 6 months of life up to 5 mg/kg weekly only after documented suboptimal response to 3 mg/kg weekly).

Suboptimal clinical response is defined as poor growth, deteriorating biochemical markers (e.g., ALT, AST), or persistent/worsening organomegaly.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required. Provider must submit documentation (office chart notes, laboratory results, enzyme assay or LIPA gene mutation testing, and current weight in kg) supporting that the member meets all approval criteria, including a confirmed diagnosis of Lysosomal Acid Lipase (LAL) deficiency.

Required supporting documentation: office notes, lab results, enzyme assay report or genetic testing (LIPA), current weight (kg).
Approval depends on demonstration of FDA‑approved diagnosis and confirmation via enzyme assay or LIPA gene mutation.

Step Therapy

Dose Escalation Requirements

Dose escalation requests require documentation of suboptimal clinical response to the prior (lower) dose and justification for the increased regimen. For rapidly progressive disease presenting within the first 6 months of life, escalation steps and maximum doses must follow dosing guidance.

Documented suboptimal clinical response is required before increasing to 3 mg/kg and again before increasing to 5 mg/kg (where applicable).
Suboptimal clinical response examples: poor growth, deteriorating biochemical markers (e.g., ALT, AST), persistent or worsening organomegaly, or unfavorable lipid parameters.

Documentation Required

Required Documentation

Provide complete clinical documentation with each request: office/clinic notes, baseline and follow‑up laboratory values (including liver enzymes and lipid panel), enzyme assay or LIPA mutation results confirming diagnosis, growth parameters, current weight (kg), and imaging or exam documentation of organomegaly when applicable.

Include baseline and recent weights and weight in kg on all requests.
Include objective measures of response: labs (ALT, AST, LDL‑C, triglycerides, HDL‑C), imaging or physical findings for organ size, and notes on clinical status (growth, survival for infants with rapidly progressive disease).

Denial Risk

Documentation and Indication Risks

Requests that lack required documentation (diagnostic confirmation, weight, relevant labs, or evidence of suboptimal response for dose increases) may be denied. Off‑label uses not addressed in this policy require review under the applicable off‑label or non‑formulary policies.

Denial risks: missing enzyme assay or LIPA mutation report; absent current weight in kg; insufficient evidence of clinical response for dose escalation requests.
Refer to CP.CPA.09, HIM.PA.154, or CP.PMN.53 (off‑label) and CP.CPA.190 / HIM.PA.103 / CP.PMN.16 (non‑formulary) as applicable.

Step Therapy Rules

Step	Requirement
Increase from lower to higher dose level	Allowed only with documented suboptimal clinical response (examples include poor growth, deteriorating biochemical markers such as ALT/AST, or persistent/worsening organomegaly).
Standard presentation (non‑rapidly progressive)	Start 1 mg/kg IV every other week; increase to 3 mg/kg every other week only upon documentation of suboptimal clinical response. Maximum dose: 3 mg/kg every other week.
Rapidly progressive disease (presenting within first 6 months of life)	Start 1 mg/kg IV once weekly; if suboptimal clinical response, increase to 3 mg/kg once weekly; if continued suboptimal response, may increase to 5 mg/kg once weekly. Maximum dose: 5 mg/kg per week.

Quantity Limits and Dose per kg

inv-16: Sebelipase alfa (Kanuma) — dose limited per kg as specified (initial, increases, and maximums)

Initial recommended starting dose1 mg/kg IV (every other week for typical presentations OR once weekly for rapidly progressive disease presenting within first 6 months)

Escalation for typical presentationsIf suboptimal response, increase to 3 mg/kg IV every other week (maximum 3 mg/kg every other week)

Escalation for rapidly progressive infant diseaseIf suboptimal response to 1 mg/kg weekly, increase to 3 mg/kg once weekly; if still suboptimal, increase up to 5 mg/kg once weekly (maximum)

Overall per-kg quantity limit statementDose limited per kg as specified — dosing and maximums must not be exceeded for authorization

OpenPayer

Clinical Policy: Sebelipase Alfa (Kanuma)

Coverage Criteria for Sebelipase alfa (Kanuma)

Initial Therapy Dosing and Requirements

Continuation Therapy Requirements

Coding and Dosing Thresholds

Provider Actions, Prior Authorization, and Documentation

Clinical Background

Definitions

Step Therapy Rules

Quantity Limits and Dose per kg

Site of Care and Administration